video
The Science of Affimers
Find out about the science behind Affimers - including why Affimers are superior to antibodies and details about our custom Affimer process...
List view / Grid view
Imaging
video
Affimers and Therapeutic Applications
Find out more about the applications of Affimers, including how Affimers can be used in the development of therapeutics...
news
Brain inflammation targeted in first Dementia Consortium drug discovery project
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
video
An Introduction to Avacta Life Sciences
This video introduces Avacta Life Sciences, part of Avacta Group plc and its flagship product, Affimers - a revolutionary new, engineered alternative to antibodies...
news
SciFluor Life Sciences patented compound SF0034 highlighted in The Journal of Neuroscience
19 June 2015 | By SciFluor Life Sciences
SciFluor Life Sciences has announced that pre-clinical research demonstrating the potential effectiveness of its patented novel compound, SF0034, for treating epilepsy and preventing tinnitus was published in the peer-reviewed publication, The Journal of Neuroscience...
news
Discovery could lead to targeted melanoma therapies
18 June 2015 | By Victoria White
Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a new study...
news
GSK invests $95m to launch Altius with goal of radically changing and improving medicines development
17 June 2015 | By Victoria White
GSK is making a substantial investment to launch the Altius Institute for Biomedical Sciences (Altius), an independent, non-profit research institute...
news
Powerful MRI scanner reveals brain cell density remains constant throughout life
15 June 2015 | By Victoria White
A powerful 9.4-Tesla MRI that provides the most detailed images of the brain to date shows that brain cell density remains constant with age...
news
LDC and Johnson & Johnson Innovation to collaborate to discover drug candidates
11 June 2015 | By Victoria White
LDC and Johnson & Johnson Innovation will collaborate to identify and accelerate innovative drug candidates for diseases with high unmet medical needs...
news
Discovery of cellular mechanism of action of tACPA in rheumatoid arthritis
11 June 2015 | By Victoria White
ModiQuest has discovered the cellular mechanism of action of its tACPA for the treatment of rheumatoid arthritis (RA) and other diseases...
news
Discovery gives hope for finding a treatment for amyotrophic lateral sclerosis
10 June 2015 | By Victoria White
A previously unknown link between the immune system and the death of motor neurons in amyotrophic lateral sclerosis has been discovered by scientists...
article
Drug Target Review – Issue #2 2015
10 June 2015 | By Drug Target Review
Included in this issue: Drug Discovery, Screening, Hit-to-Lead, Antibodies, Stem Cells, Kinases and much more...
article
Stem Cells In-Depth Focus 2015
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
This Stem Cells In-Depth Focus features articles on stem cell-derived cardiomyocytes, and their use in drug discovery and development, as well as a look at how venom could be used in stem cell differentiation...
article
Screening In-Depth Focus 2015
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…
article
Academic drug discovery in neurodegeneration; a new approach to an ageing problem
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
